GENETIC VARIANTS ON CHR2 AND CHR16 AS MARKERS FOR USE IN BREAST CANCER RISK ASSESSMENT, DIAGNOSIS, PROGNOSIS AND TREATMENT

• US 20110117545A1
• Filed: 03/26/2008
• Published: 05/19/2011
• Est. Priority Date: 03/26/2007
• Status: Abandoned Application

• Current Assignee: Decode Genetics Ehf. (Amgen Inc.)
• Original Assignee: Decode Genetics Ehf. (Amgen Inc.)
• Inventors: Manolescu, Andrei, Stacey, Simon, Sulem, Patrick
• Application Number:
  US12/302,473
• Publication Number:
  US 20110117545A1
• Time in Patent Office: Days
• US Class Current: 435/6
• CPC Class Codes: C12Q 1/6886 for cancer immunoassay for cancer G01N33/574
• CPC Class Codes: C12Q 2600/172 Haplotypes
• CPC Class Codes: Y02A 90/10 Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Abstract

The invention pertains to certain genetic variants on Chr2q14, Chr2q35 and Chr16q12 as susceptibility variants of breast cancer. Methods of risk assessment and diagnosis of increased and/or decreased susceptibility to breast cancer, using such variants are described. The invention further relates to kits for diagnosing a susceptibility to breast cancer.

Claims

1. A method for determining a susceptibility to breast cancer in a human individual, comprising determining the presence or absence of at least one allele of at least one polymorphic marker in a nucleic acid sample obtained from the individual or in a genotype dataset derived from the individual, wherein the at least one polymorphic marker is selected from the polymorphic markers set forth in any one of Table 10, Table 15 and Table 19, and markers in linkage disequilibrium therewith, and wherein the presence of the at least one allele is indicative of a susceptibility to breast cancer for the individual.

2. The method according to claim 1, wherein the at least one polymorphic marker is located within a genomic segment with the sequence as set forth in SEQ ID NO:

4, SEQ ID NO;

5 or SEQ ID NO;

6.

3. The method according to claim 1, wherein the at least one polymorphic marker is selected from the markers set forth in any one of Table 10, Table 15 and Table 19.

4. The method according to claim 1, wherein the at least one polymorphic marker is selected from rs4848543 (SEQ ID NO:

1), rs3803662 (SEQ ID NO;

     3) and rs13387042 (SEQ ID NO;

2).

5. The method according to claim 1, further comprising assessing the frequency of at least one haplotype in the individual.

6. The method of claim 1, wherein the susceptibility conferred by the presence of the at least one allele or haplotype is increased susceptibility.

7. The method according to claim 6, wherein the presence of allele A in marker rs4848543, allele T in marker rs3803662 and/or allele A in marker rs13387042 is indicative of increased susceptibility to breast cancer.

8. The method according to claim 6, wherein the presence of the at least one allele or haplotype is indicative of increased susceptibility to breast cancer with a relative risk (RR) or odds ratio (OR) of at least 1.20.

9. The method according to claim 6, wherein the presence of the at least one allele or haplotype is indicative of increased susceptibility with a relative risk (RR) or odds ratio (OR) of at least 1.25.

10. The method according to claim 1, wherein the susceptibility conferred by the presence of the at least one allele or haplotype is decreased susceptibility.

11. The method of claim 1, further comprising analyzing a sample comprising genomic DNA from a human individual or a genotype dataset derived from a human individual for the presence or absence of at least one at-risk allele of at least one at-risk variant for breast cancer not in linkage disequilibrium with any one of the markers set forth in Table 10, Table 15 and Table 19.

12. The method of claim 1, comprising determining the presence or absence of at least one allele in at least two polymorphic markers, wherein the presence of the at least one allele in the at least two polymorphic markers is indicative of an increased susceptibility to breast cancer.

13. The method according to claim 1, further comprising a step of determining the presence or absence of at least one high penetrant genetic factor for breast cancer in a nucleic acid sample obtained from the individual or in a genotype dataset derived from the individual.

14. The method according to claim 13, wherein the high penetrant genetic factor is BRCA2 999del5.

15. The method according to claim 1, further comprising assessing the individual for estrogen receptor or progesterone receptor status.

16. The method according to claim 15, wherein estrogen receptor positive status or progesterone receptor positive status in the individual is associated with increased risk of breast cancer.

17. The method according to claim 16, wherein the increased risk of breast cancer is associated with rs13387042 allele A and/or rs3803662 allele T, and markers in linkage disequilibrium therewith.

18. The method of claim 1, further comprising analyzing non-genetic information to make risk assessment, diagnosis, or prognosis of the individual.

19. The method of claim 18, wherein the non-genetic information is selected from age, gender, ethnicity, socioeconomic status, previous disease diagnosis, medical history of subject, family history of breast cancer, biochemical measurements, and clinical measurements.

20. The method of claim 1, further comprising calculating combined risk.

22. The method according to claim 20, wherein the at least one polymorphic marker is rs4848543 (SEQ ID NO:

1), and markers in linkage disequilibrium therewith.

21. A method of determining risk of developing at least a second primary tumor in an individual previously diagnosed with breast cancer, the method comprising determining the presence or absence of at least one allele of at least one polymorphic marker in a nucleic acid sample obtained from the individual, or in a genotype dataset derived from the individual, wherein the at least one polymorphic marker is selected from the polymorphic markers set forth in any one of Table 10, Table 15 and Table 19, and markers in linkage disequilibrium therewith,

and wherein the presence of the at least one allele is indicative of risk of developing at least a second primary tumor.

23. A kit for assessing susceptibility to breast cancer in a human individual, the kit comprising reagents for selectively detecting at least one allele of at least one polymorphic marker in the genome of the individual, wherein the polymorphic marker is selected from the markers set forth in Tables 10, 15 and 19, and markers in linkage disequilibrium therewith, and wherein the presence of the at least one allele is indicative of a susceptibility to breast cancer.

24-28. -28. (canceled)

29. An apparatus for determining a genetic indicator for breast cancer in a human individual, comprising:

a computer readable memory; and

a routine stored on the computer readable memory;

wherein the routine is adapted to be executed on a processor to analyze marker and/or haplotype information for at least one human individual with respect to at least one polymorphic marker selected from the markers set forth in Table 10, Table 15 and Table 19 and markers in linkage disequilibrium therewith, and generate an output based on the marker or haplotype information, wherein the output comprises an individual risk measure of

the at least one marker or haplotype as a genetic indicator of breast cancer for the human individual.

30. The apparatus of claim 29, wherein the routine further comprises a risk measure for breast cancer associated with the at least one marker allele and/or haplotype, wherein the risk measure is based on a comparison of the frequency of at least one allele of at least one polymorphic marker and/or haplotype in a plurality of individuals diagnosed with breast cancer and an indicator of the frequency of the at least one allele of at least one polymorphic marker and/or haplotype in a plurality of reference individuals, and wherein the individual risk for the human individual is based on a comparison of the carrier status of the individual for the at least one marker allele and/or haplotype and the risk measure for the at least one marker allele and/or haplotype.

31. The apparatus according to claim 29, wherein the at least one polymorphic marker is selected from rs4848543 (SEQ ID NO:

1), rs3803662 (SEQ ID NO;

     3) or rs13387042 (SEQ ID NO;

     2), and markers in linkage disequilibrium therewith.

32. (canceled)

33. (canceled)

34. A method of identification of a marker for use in assessing susceptibility to breast cancer, the method comprising:

d. identifying at least one polymorphic marker in linkage disequilibrium with at least one of the markers within the genomic segments with sequence as set forth in SEQ ID NO;

4, SEQ ID NO;

5 and SEQ ID NO;

6;

e. determining the genotype status of a sample of individuals diagnosed with, or having a susceptibility to, breast cancer; and

f. determining the genotype status of a sample of control individuals;

wherein a significant difference in frequency of at least one allele in at least one polymorphism in individuals diagnosed with, or having a susceptibility to, breast cancer, as

compared with the frequency of the at least one allele in the control sample is indicative of the at least one polymorphism being useful for assessing susceptibility to breast cancer.

35. The method according to claim 34, wherein an increase in frequency of the at least one allele in the at least one polymorphism in individuals diagnosed with, or having a susceptibility to, breast cancer, as compared with the frequency of the at least one allele in the control sample is indicative of the at least one polymorphism being useful for assessing increased susceptibility to breast cancer.

36. The method according to claim 34, wherein a decrease in frequency of the at least one allele in the at least one polymorphism in individuals diagnosed with, or having a susceptibility to, breast cancer, as compared with the frequency of the at least one allele in the control sample is indicative of the at least one polymorphism being useful for assessing decreased susceptibility to, or protection against, breast cancer.

37. The method according to claim 34, wherein the at least one marker within SEQ ID NO:

4 is selected from the markers set forth in Table 20.

38. The method according to claim 34, wherein the at least one marker within SEQ ID NO:

5 is selected from the markers set forth in Table 21.

39. The method according to claim 34, wherein the at least one marker within SEQ ID NO:

6 is selected from the markers set forth in Table 22.

40. The method according to claim 34, wherein the at least one polymorphic marker in linkage disequilibrium with at least one of the markers within the genomic segments with sequence as set forth in SEQ ID NO:

4, SEQ ID NO;

5 and SEQ ID NO;

6 is selected from rs4848543 (SEQ ID NO;

     1), rs3803662 (SEQ ID NO;

3) and rs13387042 (SEQ ID NO;

2).

41. A method of genotyping a nucleic acid sample obtained from a human individual at risk for, or diagnosed with, breast cancer, comprising determining the presence or absence of at least one allele of at least one polymorphic marker in the sample, wherein the at least one marker is selected from the group consisting of the markers set forth in Table 10, Table 15 and Table 19, and markers in linkage disequilibrium therewith, and wherein the presence or absence of the at least one allele of the at least one polymorphic marker is indicative of a susceptibility of breast cancer.

42. The method of claim 41, wherein the at least one marker is selected from rs4848543 (SEQ ID NO:

1), rs3803662 (SEQ ID NO;

3) and rs13387042 (SEQ ID NO;

2).

43. The method according to claim 41, wherein genotyping comprises amplifying a segment of a nucleic acid that comprises the at least one polymorphic marker by Polymerase Chain Reaction (PCR), using a nucleotide primer pair flanking the at least one polymorphic marker.

44. The method according to claim 41, wherein genotyping is performed using a process selected from allele-specific probe hybridization, allele-specific primer extension, allele-specific amplification, nucleic acid sequencing, 5′

-exonuclease digestion, molecular beacon assay, oligonucleotide ligation assay, size analysis, and single-stranded conformation analysis.

45. The method according to claim 44, wherein the process comprises allele-specific probe hybridization.

46. The method according to claim 45, wherein the process comprises DNA sequencing.

47. The method according to claim 41, comprising:

3) contacting copies of the nucleic acid with a detection oligonucleotide probe and an enhancer oligonucleotide probe under conditions for specific hybridization of the oligonucleotide probe with the nucleic acid;

wherein

a) the detection oligonucleotide probe is from 5-100 nucleotides in length and specifically hybridizes to a first segment of a nucleic acid whose nucleotide sequence is given by SEQ ID NO;

4, SEQ ID NO;

5 or SEQ ID NO;

6;

b) the detection oligonucleotide probe comprises a detectable label at its 3′

terminus and a quenching moiety at its 5′

terminus;

c) the enhancer oligonucleotide is from 5-100 nucleotides in length and is complementary to a second segment of the nucleotide sequence that is 5′

relative to the oligonucleotide probe, such that the enhancer oligonucleotide is located 3′

relative to the detection oligonucleotide probe when both oligonucleotides are hybridized to the nucleic acid; and

d) a single base gap exists between the first segment and the second segment, such that when the oligonucleotide probe and the enhancer oligonucleotide probe are both hybridized to the nucleic acid, a single base gap exists between the oligonucleotides;

4) treating the nucleic acid with an endonuclease that will cleave the detectable label from the 3′

terminus of the detection probe to release free detectable label when the detection probe is hybridized to the nucleic acid; and

5) measuring free detectable label, wherein the presence of the free detectable label indicates that the detection probe specifically hybridizes to the first segment of the nucleic acid, and indicates the sequence of the polymorphic site as the complement of the detection probe.

48. (canceled)

49. A method of predicting prognosis of an individual diagnosed with breast cancer, the method comprising determining the presence or absence of at least one allele of at least one polymorphic marker in a nucleic acid sample obtained from the individual, wherein the at least one polymorphic marker is selected from the group consisting of the polymorphic markers set forth in Table 10, Table 15 and Table 19, and markers in linkage disequilibrium therewith, wherein the presence of the at least one allele is indicative of a worse prognosis of the breast cancer in the individual.

50. (canceled)

51. (canceled)

52. (canceled)

53. A computer-readable medium on which is stored:

d. an identifier for at least one polymorphic marker;

e. an indicator of the frequency of at least one allele of said at least one polymorphic marker in a plurality of individuals diagnosed with breast cancer; and

f. an indicator of the frequency of the least one allele of said at least one polymorphic markers in a plurality of reference individuals;

wherein the at least one polymorphic marker is selected from the polymorphic markers set forth in Table 10, Table 15 and Table 19, and polymorphic markers in linkage disequilibrium therewith.

54. The medium according to claim 53, wherein the polymorphic marker is selected from rs4848543 (SEQ ID NO:

1), rs3803662 (SEQ ID NO;

3) and rs13387042 (SEQ ID NO;

2), and markers in linkage disequilibrium therewith.

55. The medium according to claim 53, further comprising information about the ancestry of the plurality of individuals.

56. The medium according to claim 53, wherein linkage disequilibrium is characterized by numerical values of r² of at least 0.2 and/or values of |D′

| of at least 0.8.